Saturday 17 October 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
16.20
2.59
−13.78%
Follow OMER
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 9.60 | 5.56 |
P/S ratio |
— | — | 8.46 | 7.05 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (52.35) | 165.34 | |
P/B ratio |
— | — | 0.00 | 0.00 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 8.67 | 6.87 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (8.21) | (9.73) | |
EV/FCF |
— | — | (8.20) | (9.72) | |
Quick Ratio |
0.53 | 2.34 | 2.48 | 1.61 | |
Current Ratio |
0.89 | 2.76 | 3.03 | 1.95 | |
Net Debt/EBITDA |
(5.37) | (1.91) | (0.10) | (20.37) | |
Debt/Assets |
95.09% | 69.28% | 47.82% | 33.90% | |
Debt/Equity |
(0.80) | (1.86) | (2.16) | (1.89) | |
Asset Turnover |
0.00 | 0.00 | 0.34 | 0.40 | |
Operating CF/Net income |
0.60 | (0.46) | (0.26) | 0.31 | |
Capex/Depreciation |
(0.05) | 0.00 | 0.00 | (0.03) | |
Interest Coverage |
1.98 | (3.33) | (2.96) | 0.01 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 135.02% | 48.36% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 135.14% | 48.58% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 19.09% | 5.68% | |
Graham Net Nets |
— | — | (0.22) | (0.22) | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | 10.42% | 17.98% | |
Free Cash Flow Yield |
— | — | (12.49%) | (10.02%) | |
Revenue per Share |
0.00 | 0.00 | 0.14 | 0.40 | |
Operating CF per Share |
(0.28) | (0.63) | (0.20) | 0.06 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.63) | (0.20) | 0.06 | |
Cash per Share |
0.54 | 2.71 | 1.88 | 1.83 | |
Shareholders Equity per Share |
(3.33) | (1.91) | (0.88) | (0.71) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.33) | (1.91) | (0.88) | (0.71) | |
Free Cash Flow |
(18.48) | (39.84) | (14.51) | 4.10 | |
Working Capital |
(8.95) | 137.61 | 120.91 | 90.28 | |
Capital Expenditures |
(0.01) | 0.00 | — | (0.04) | |
Net Current Asset Value |
(334.38) | (231.20) | (169.15) | (152.94) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.65 | 9.33 | 9.55 | 13.79 | |
Average Payables |
10.11 | 5.33 | 4.89 | 7.59 | |
Average Inventory |
— | — | 0.77 | 1.02 | |
Average Assets |
249.52 | 301.36 | 260.67 | 243.70 | |
Average Common Equity |
(187.32) | (151.92) | (138.44) | (140.02) |
Columns are period end dates